Articles tagged with Lymphoma
A multicenter clinical trial showed that combining brentuximab vedotin with standard chemotherapy reduced event-free survival by 10%, decreasing relapse risk. This targeted therapy approach may set the stage for FDA approval and improve cure rates without adding significant long-term toxicity.
A multistate study found that mRNA COVID vaccines were less effective in immunocompromised adults, with protection rates ranging from 34% to 71% after multiple doses. The study emphasizes the importance of non-pharmaceutical interventions, such as masks and antibody treatment, for additional protection against severe COVID-19.
The NCCN Annual Congress on Hematologic Malignancies will address key findings on chronic lymphocytic leukemia management and CAR T-cells in diffuse large B-cell lymphoma. The event also features updates on immunotherapies in multiple myeloma treatment.
Researchers at the University of South Australia are using new technologies to speed up blood cancer diagnosis and treatment. The project aims to identify genetic variants that cause cancer, enabling clinicians to provide targeted treatments and improve patient management.
Researchers found that 12% of cancer survivors lived in poverty, experiencing negative effects on physical and mental health. Financial burden of cancer care persists years after diagnosis, leading to poor health outcomes and increased mortality.
Scientists discover that methotrexate causes oxidative damage to the cerebrospinal fluid and choroid plexus, leading to cognitive impairment. Adding antioxidants to the CSF may protect against this damage, offering a potential treatment for 'chemo brain'. Researchers are exploring other chemotherapy drugs and testing antioxidant treatm...
Scientists at St. Jude Children's Research Hospital studied 36 families affected by Hodgkin lymphoma and identified 44 novel genetic variants linked to cancer predisposition, including PAX5, GATA3, IRF7, EEF2KMT, and POLR1E. The study provides new insights into the disease and may help identify potential targets for new treatments.
Researchers have identified a potential new therapeutic approach for angioimmunoblastic T-cell lymphoma (AITL) by understanding the mechanism of its development. A team from the University of Tsukuba found that B cells accumulate mutations in genes controlling genetic material packaging, leading to AITL.
Researchers developed a method to produce generic CAR T cells from induced pluripotent stem cells (iPS cells), which could be produced at scale for multiple patients. The new cells showed enhanced anti-tumor activity and comparable efficacy to current clinical-grade cells.
A recent study published in CANCER highlights the growing concern among Hodgkin lymphoma survivors. The analysis found that individuals with early-stage HL are now at a higher risk of death from cardiovascular disease compared to cancer after approximately 60 and 120 months of follow-up. This indicates that more effective measures are ...
Researchers from Mayo Clinic Comprehensive Cancer Center found that adding brentuximab vedotin to standard chemotherapy treatment improves overall survival in patients with Hodgkin Lymphoma. The study showed that the drug has a positive impact on overall survival, regardless of other treatments administered later in the course of care.
This analysis evaluated changes in short-course radiation therapy use and spending on low-grade lymphoma patients from 2015 to 2019. The study found a significant increase in the use of this therapy among Medicare beneficiaries, suggesting potential cost savings and improved patient outcomes.
The study found that autologous stem cell transplantation (ASCT) was underutilized in community settings, but maintenance therapy after standard therapy improved outcomes for patients over 65. Maintenance rituximab after bendamustine and chemotherapy regimens also significantly extended times to disease progression and overall survival.
The study found that combination chemoimmunotherapy with ibrutinib improved progression-free survival over standard chemoimmunotherapy in patients with previously untreated mantle cell lymphoma. The median PFS was 80.6 months with the ibrutinib combination versus 52.9 months in the control arm.
MD Anderson research highlights new treatments for skin cancers, including novel therapies. The institution also showcased improved goals of care programs, which demonstrated significant reductions in ICU mortality and improved patient outcomes during the COVID-19 pandemic.
A population-scale study found COVID-19 vaccination is effective in most cancer patients but offers lower protection and wanes quickly. Vaccine effectiveness was lower (65.5%) in cancer patients compared to the general population (69.8%), with higher hospitalization and death risks despite vaccination.
A new lymphoma treatment, zanubrutinib, has been found to be effective in 80% of patients with marginal zone lymphoma, resulting in significant cancer shrinkage. However, its impact on follicular lymphoma is less pronounced.
A study published by Mayo Clinic Cancer Center investigates the reasons for decreasing remission rates for patients with non-Hodgkin lymphoma treated with CAR-T cell therapy. The team found that a gene called TIGIT drives CAR-T cell exhaustion and dysfunction, suggesting its blocking strategy may improve treatment efficacy.
The study found significant heterogeneity among non-hematopoietic cells (NHCs) in human lymph nodes, with subgroups exhibiting distinct transcriptional changes and interaction patterns with malignant cells. This discovery may lead to the identification of potential biomarkers for therapeutic approaches.
Patients with serious illnesses seek cosmetic procedures to maintain their physical and mental well-being, as well as to become comfortable in social settings. The study found that these procedures are often chosen for noninvasive treatments and endorsed by doctors, friends, and family.
Dr. Elaine S. Jaffe is being recognized for her pioneering work in hematopathology, including the discovery of novel pathological entities and her development of standardized diagnostic criteria for lymphoma and leukemia. She has also made significant contributions to advancing cancer research, diagnosis, treatment, and prevention.
A new study by University of Southampton researchers found that a third COVID-19 vaccination improves immune responses in blood cancer patients. The study showed that 92% of patients without recent anti-CD20 treatment had improved antibody responses after the third dose.
Scientists have identified diagnostic features of circulating tumour DNA (ctDNA) in blood samples, which can predict treatment response and patient outcome in aggressive lymphoma. The study reveals significant heterogeneity among patients, with high ctDNA levels associated with poorer survival rates.
A new blood test developed at Hebrew University of Jerusalem detects immune and inflammatory activity in tissues by monitoring circulating DNA fragments. This method provides accurate information about immune processes in remote tissues, removing the need for invasive measures.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated axi-cel's efficacy in treating high-risk lymphoma patients with enhanced responses and prolonged survival benefits. The study showed improved outcomes for patients with indolent non-Hodgkin lymphoma, with an estimated 81% overall survival rate at 24 months.
A recent study by NTU Singapore and Singapore General Hospital found that mutations in the DDX3X gene are responsible for chemotherapy resistance in some blood cancer patients. The study also discovered that STAT inhibitors can effectively kill lymphoma cells with DDX3X mutations, providing hope for new treatment options.
A new treatment target for lymphoma has been identified as protein KDM5, which may reverse the effects of KMT2D mutations in cancer cells. The international collaboration aims to identify patient groups most likely to benefit from this type of treatment and explore its therapeutic potential across various lymphoma subtypes.
A recent study found that antibiotic resistance rates for Helicobacter pylori are decreasing in European countries. The use of three antibiotics over 10-14 days resulted in success rates of over 90%. The researchers hope to reduce antibiotic consumption to prevent further resistance.
Researchers found that higher lymphoma volume at diagnosis was associated with increased risk of recurrence. This could lead to improved patient outcomes by selecting the most appropriate treatment. The study also explored PET-based measures of initial disease burden, which may help predict patients' risk of recurrence.
A study found that younger B-cell non-Hodgkin lymphoma survivors are at a higher risk of developing age-related diseases, including renal failure, pneumonia, and nutritional deficiencies. The research suggests that aggressive treatment regimens may be the underlying factor contributing to this increased risk.
Cancer cells alter the large blood vessels in lymph nodes, disrupting their function and allowing tumor cells to evade attack by the immune system. The researchers identified identical findings in mice and humans, providing a deeper understanding of how lymphomas protect themselves from the body's defenses.
A team of scientists developed a drug-like molecule that can counteract the effects of mutated epigenetic regulators, which are known to drive certain types of cancer. The molecule targets the 'reader' CBX8, which is critical for the proliferation of cancer cells, but more dispensable in healthy cells.
A new imaging technique using PET/MR and a PET tracer directed against CXCR4 shows high accuracy in detecting MALT lymphomas of the stomach, potentially reducing the need for repeated gastroscopies. The study found that [68Ga]Pentixafor PET/MR achieved 97% accuracy in detecting tumours compared to gastroscopy.
A modified chemotherapy regimen for Burkitt lymphoma has been developed, combining CODOX-M and IVAC with rituximab, to reduce toxicity and improve survival rates. The study found a higher overall survival rate and lower frequency of severe side effects compared to standard regimens.
Researchers at the University of Southampton have identified a unique change in B cells that allows them to receive signals from molecules called lectins, enabling tumor growth. This discovery could pave the way for new treatments and early cancer detection methods.
A Korean population-based cohort study found that cancer, particularly multiple myeloma and leukemia, is associated with an increased risk of kidney failure. The study included approximately 825,000 patients with cancer compared to twice as many without cancer, matched on other characteristics.
A new study by CNIO researchers has found that blocking the RagC protein's signals can delay the onset of follicular lymphoma in animal models. The strategy may also be effective in treating autoimmune diseases.
The RESILIENCE project seeks to prevent anthracycline-induced cardiotoxicity in cancer patients through remote ischaemic preconditioning, with over 600 patients enrolled in a randomised clinical trial. Cardiac function will be evaluated using state-of-the-art cardiac magnetic resonance imaging.
A new class of drugs inhibiting the SOX 11 oncogene has been discovered by researchers at Mount Sinai, showing promising results in treating mantle cell lymphoma. The discovery could lead to new therapies for a disease resistant to existing treatments.
A new preclinical study from the University of Texas MD Anderson Cancer Center found that cord blood-derived NK cells combined with AFM13 displayed potent anti-tumor activity against CD30+ lymphoma cells. The therapy showed improved tumor control and survival in animal models with minimal side effects.
A phase 2 clinical trial found that brentuximab vedotin achieved excellent outcomes in high-risk pediatric Hodgkin lymphoma patients, with a three-year survival rate of 99% and reduced radiation exposure. The targeted therapy also minimized side effects, particularly neuropathy.
A new study by Uppsala University found that unmarried patients and those with low educational attainment are less likely to be treated with a stem-cell transplantation for mantle cell lymphoma. The study suggests that this may result in poorer survival rates.
A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab. In a non-Hodgkin's lymphoma mouse model, the treatment substantially increased rituximab binding and antibody-dependent cellular cytotoxicity activity, resulting in significant tumor growth delay.
Researchers at Josep Carreras Leukaemia Research Institute discovered a marker predicting aggressive clinical course in Hodgkin's lymphoma patients. The marker allows identifying patients with poor evolution, enabling early intervention and improved treatment outcomes.
A new immunotherapeutic agent has been shown to significantly improve treatment outcomes for children and adolescents with advanced non-Hodgkin lymphoma, particularly Burkitt lymphoma. The agent, rituximab, in combination with chemotherapy, has a cure rate of over 95% and reduces the risk of disease progression by up to 70%.
A phase III trial showed rituximab significantly improves the three-year survival rate for pediatric patients with advanced B-cell non-Hodgkin lymphoma, decreasing treatment failures by 70 percent.
Researchers discovered that tumors in lymph nodes are distinct from solid tumors, with a unique pattern of branching and signaling pathways. They identified VEGF-C as the primary driver of angiogenesis in early stages of lymphoma, which can be targeted to slow tumor growth.
A new study reveals that MNT is required for the survival of MYC-driven lymphoma cells, suggesting a promising new approach for treating this type of cancer. Inhibiting MNT may also make tumours more susceptible to other drugs, offering hope for improved treatments.
A randomized, double-blind trial compared the safety and efficacy of F14512 and etoposide phosphate in dogs with spontaneous non-Hodgkin lymphoma. F14512 demonstrated significant antitumor activity and clinical benefits, particularly in P-glycoprotein overexpressing lymphomas.
A new analysis reveals that donor stem cell transplantation following PD-1 treatment is generally safe and produces good outcomes for patients with Hodgkin lymphoma. Post-transplant treatment with cyclophosphamide may also lead to improved results, reducing rates of acute GVHD and relapse.
A new study from Georgetown University Medical Center found that 38 patients with follicular lymphoma who were in remission for at least two years did not show any evidence of the disease in their blood. This suggests that these patients may be disease-free and could have a lifelong disease status.
Researchers discovered that chronic inflammatory processes in aging brains lead to lymphoma cells being retained in the brain tissue instead of being released back into the blood. The NF-kappaB signaling pathway and CCL19 play a crucial role in this process, allowing lymphoma cells to multiply and develop tumors.
Follicular lymphoma originates from mutations in RagC gene on mTOR signalling pathway, affecting B cell growth. Rapamycin treatment delays progression and prolongs survival in mice with RagC mutations.
A study found a statistically significant association between BRCA2 mutations and increased risk of non-Hodgkin lymphoma in children. Additionally, BRCA2 mutations were not associated with an increased risk of Hodgkin lymphoma.
Researchers at UNC Lineberger Comprehensive Cancer Center discovered a hyperactive cell signal contributing to tumor growth in aggressive blood cancer. They developed an experimental therapeutic compound, UNC3810A, that targeted and slowed tumor growth by blocking the hyperactive Tyro3 protein.
Researchers discovered MYC's new roles in cancer cell efficiency and protein production. High MYC levels stimulate specific mRNAs translation into respiratory complex proteins, fueling growth. This study reveals MYC regulates metabolic enzymes and immune receptors in lymphoma cells.
Researchers from Johns Hopkins Medicine found a distinct subtype of primary central nervous system lymphoma suitable for surgical removal, offering improved outcomes and potential cure rates. The study suggests a shift in treatment approach, moving away from traditional biopsy, radiotherapy, and high-dose chemotherapy.
Researchers identified LTA as a key player in Hodgkin's lymphoma progression, activating NF-kB and promoting cancer cell proliferation. This discovery suggests LTA could be a target for new treatment strategies.
Researchers from Colorado State University found that dogs with omega-3 fatty acid supplements or hypothyroidism are less likely to develop T-zone lymphoma. The study also revealed a link between defective genes and the disease, suggesting potential new avenues for research and prevention.
A Phase II trial at MD Anderson Cancer Center showed umbralisib to be an effective treatment for patients with relapsed marginal zone lymphoma, achieving a 55% partial or complete response rate. The drug was well-tolerated, with a 71% progression-free survival after one year.